The Woodlands-based company strikes obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
American Association of Individual Investors9d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 77.50%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 77.50%, which has investors questioning if this is right time ...
American Association of Individual Investors6d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 25.32%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.
Houston-area company may be developing next hot weight-loss drug
A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. Lexicon ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...
STAT9d
Novo Nordisk sets sights on new type of oral obesity drug
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Fierce Biotech9d
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Lexicon Pharmaceuticals’ (LXRX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...
Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...